A phase 2 clinical trial – the BANDIT (Baricitinib in new onset type 1 diabetes) trial – based on findings by scientists at St Vincent's Institute of Medical Research (SVI) in Melbourne, began in November 2020.
Researchers at SVI have found that the drug baricitinib (Olumiant), currently in use as a treatment for rheumatoid arthritis, may help people who have type 1 diabetes to produce insulin for longer after diagnosis. It is expected to stop the immune system from attacking the insulin-producing cells in the pancreas. There are no approved treatments that are able to do this.
If you have a patient aged 10 – 30 years old, who has been diagnosed with type 1 diabetes within the last 100 days, they may be eligible to participate in the clinical trial.
This Australian-based trial is funded by Juvenile Diabetes Research Foundation (JDRF). Participants must attend one of three sites in Melbourne: The Royal Melbourne Hospital, The Royal Children’s Hospital and St Vincent’s Hospital Melbourne or one site in Adelaide – the Women’s and Children’s Hospital.
Participants will be randomly assigned to either baricitinib or placebo. Two thirds of the trial participants will receive baricitinib and one third will receive the placebo.
The trial will last for two years. In the first year, participants will take baricitinib or placebo tablets orally once per day. They will be required to visit the trial site 12 times during the first year. In the second year, participants return twice for tests and monitoring.
Participants will not be paid but will be reimbursed for any reasonable travel, parking, meals and other expenses associated with the research project visit.
How you can help
We would appreciate your assistance in telling eligible patients about this opportunity, which will advance type 1 diabetes research and may help people who are diagnosed with type 1 diabetes in the future.
For more information, or to see if your patient is eligible, please contact Associate Professor John Wentworth via email or by telephone on (03) 9342 7344 or the SVI BANDIT trial coordinator via email or by telephone on 0450 323 962.
For more information, please refer your patients to this website.
Please note that all applications to participate in the BANDIT trial will be assessed, but as we have almost reached our maximum participant capacity, we cannot guarantee your place in the trial. Thank you for your interest and understanding.
This information is available in the form of an information sheet, which you can download or save. A participant information sheet is also available here.
Other clinical trial information
If your patients don’t meet the criteria for this clinical trial, but would like to participate in another type 1 diabetes clinical trial in Australia, please refer them to: